Anti-skin-aging cyclic hexapeptide compound and preparation method thereof
The anti-skin aging ring hexapeptide compounds prepared through synthesis and ring formation reactions solve the problem of limited amount of peptide addition in existing skin care products, significantly improving the anti-wrinkle and barrier enhancement effect, and are suitable for cosmetics.
Patent Information
- Application Number
- CN202411113431.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-05-19
- Publication Date
- 2024-11-08
AI Technical Summary
The amount of peptides added in existing skin care products is limited by the stability of the formula, resulting in a single skin effect and slow effect, and the anti-wrinkle and barrier enhancement effects cannot be fully utilized.
Prepare anti-skin aging cyclic hexapeptide compounds, synthesize chain-like hexapeptide compounds and obtain cyclic hexapeptide compounds through ring-forming reactions, promote the expression of collalpb and FLG genes, enhance the formation of collagen and silk polyprotein, and enhance the function of skin barrier .
Significantly enhances anti-wrinkle effect and skin barrier function, providing better skin repair effects, suitable for cosmetics.
Smart Images

Figure CN118909048A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of polypeptide and derivative synthesis, and specifically relates to an anti-skin aging cyclohexapeptide compound and a preparation method thereof. Background Art
[0002] Skin is an important and largest organ covering the entire body surface. It is the protector of the internal organs and tissues of the human body. At the same time, it is also the effector organ of the internal organs, spirit and surrounding environment, and plays a particularly important role in the health and beauty of the human body. In the process of defense and care of natural skin aging, active biological peptides also play a unique and important physiological role, such as proliferation of skin tissue cells, cell chemotaxis and migration, repair and regeneration, angiogenesis and reconstruction, pigment formation and removal, protein synthesis and secretion, metabolism and regulation, etc.
[0003] Peptides, especially some small molecule peptides, are now widely used in beauty cosmetics formulas because they are non-toxic, easily absorbed by the skin, and have special physiological activities after absorption, which can improve certain skin problems from the outside to the inside. There are various cosmetics or skin care products on the market, but most skin care products only add a certain type of peptide as the active ingredient of the skin care products, so the effect obtained on the skin is relatively simple and slow to take effect; moreover, most of the skin care products on the market that use peptides as active ingredients directly add peptides or peptide concentrates to conventional skin care product matrices. Considering the preparation and stability of the entire formula, the amount of peptide added will be limited. Summary of the invention
[0004] The purpose of the present invention is to provide an anti-skin aging cyclic hexapeptide compound and a preparation method thereof. The hexapeptide compound has better skin repair effect and significantly enhanced anti-wrinkle effect; at the same time, it has better skin barrier enhancement effect and can be better applied in the field of cosmetics.
[0005] The technical solution adopted by the present invention to achieve the above-mentioned purpose is: An anti-skin aging cyclohexapeptide compound, the general structural formula of which is shown in Formula I: I, In the formula, n is independently selected from 0 or a natural number; R1, R2 are independently selected from H, (CH2) m COOA1, (CH2) m CONA2A3, (CH2) m SA4, m is independently selected from 0 or a natural number; A1, A2, A3, A4 are independently selected from H, unsubstituted or substituted C 6-30 Aryl, C 2-18Heteroaryl, C 1-24 Alkyl, C 3-24 Cycloalkyl, C 3-10 Heterocycloalkyl, C 2-24 Alkenyl, C 5-24 Cycloalkenyl, C 2-24 Alkynyl, C 8-24 One of the cycloalkynyl groups; the substitution is by OH, NH2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Substituted by any one or more of heterocycloalkyl, phenyl, and heteroaryl; R3, R4, R5, R6, R7, R8 are independently selected from H, OH, unsubstituted or substituted C 6-30 Aryl, C 2-18 Heteroaryl, C 1-24 Alkyl, C 3-24 Cycloalkyl, C 3-10 Heterocycloalkyl, C 2-24 Alkenyl, C 5-24 Cycloalkenyl, C 2-24 Alkynyl, C 8-24 One of the cycloalkynyl groups; the substitution is by OH, NH2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 The present invention first prepares a series of chain-shaped hexameric polypeptides, which have good skin repair effects and can promote collalb Gene expression, increase the amount of type I collagen production, thereby enhancing the smoothness of the skin, anti-wrinkle effect is significant; and has a good effect of promoting FLG The effect of gene expression can promote the formation of filaggrin, enhance the moisture retention capacity of the stratum corneum, improve the state of the stratum corneum, and thus effectively enhance the skin barrier function. Then, the chain hexapeptide is cyclized to obtain the corresponding series of cyclic hexapeptide compounds, which have better skin repair effect and better promotion effect. collalb Gene expression ability can significantly improve its effect of promoting collagen formation, which can better improve skin condition and have a better anti-wrinkle effect; at the same time, the series of cyclic hexapeptide compounds prepared have better promotion FLG The gene expression ability can significantly improve its effect of promoting the formation of related proteins, can better improve the state of the skin stratum corneum, and play a better role in strengthening the skin barrier. The anti-skin aging cyclohexapeptide compounds prepared by the present invention have great application prospects in the field of cosmetics.
[0006] The present invention also discloses an anti-skin aging cyclohexapeptide compound, the general structural formula of which is shown in Formula II: II, In the formula, n is independently selected from 0 or a natural number; R1, R2 are independently selected from H, (CH2) m COOA1, (CH2) m CONA2A3, (CH2) m SA4, m is independently selected from 0 or a natural number; A1, A2, A3, A4 are independently selected from H, unsubstituted or substituted C 6-30 Aryl, C 2-18 Heteroaryl, C 1-24 Alkyl, C 3-24 Cycloalkyl, C 3-10 Heterocycloalkyl, C 2-24 Alkenyl, C 5-24 Cycloalkenyl, C 2-24 Alkynyl, C 8-24 One of the cycloalkynyl groups; the substitution is by OH, NH2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 Substituted by any one or more of heterocycloalkyl, phenyl, and heteroaryl; R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 independently selected from H, OH, unsubstituted or substituted C 6-30 Aryl, C 2-18 Heteroaryl, C 1-24 Alkyl, C 3-24 Cycloalkyl, C 3-10 Heterocycloalkyl, C 2-24 Alkenyl, C 5-24 Cycloalkenyl, C 2-24 Alkynyl, C 8-24 One of the cycloalkynyl groups; the substitution is by OH, NH2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, C 3-7 It is substituted by any one or more of heterocycloalkyl, phenyl and heteroaryl.
[0007] Furthermore, n is selected from one of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.
[0008] It should be noted that when n is 0, it represents that the carbonyl group is directly connected to the five-membered ring or the six-membered ring.
[0009] Furthermore, m is selected from one of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24.
[0010] Further, R1 is the same as R2.
[0011] Further, R1 and R2 are selected from H, (CH2) m COOH, (CH2) m One of CONH2, m is independently selected from 0 or a natural number.
[0012] Furthermore, m is selected from 1 or 2; n is selected from 0 or 1.
[0013] Further, R3 is the same as R8, and / or R4 is the same as R7, and / or R5 is the same as R6.
[0014] Preferably, R3 is the same as R8, R4 is the same as R7, and R5 is the same as R6.
[0015] Furthermore, R4 and R7 are selected from H or OH.
[0016] Furthermore, R 3 With R 10 Same and / or R 4 With R 9 Same, and / or R 5 With R 8 Same, and / or R 6 With R 7 same.
[0017] Preferably, R 3 With R 10 Same, R 4 With R 9 Same, R 5 With R 8 Same, R 6 With R 7 same.
[0018] Preferably, the structure of the anti-skin aging cyclohexapeptide compound is as shown in Formula IV: IV.
[0019] More preferably, the structure of the anti-skin aging cyclohexapeptide compound is as shown in Formula V: V.
[0020] The invention also discloses a method for preparing the anti-skin aging cyclohexapeptide compound, comprising: firstly synthesizing a chain hexapeptide, and then preparing the cyclohexapeptide compound through a ring-forming reaction.
[0021] Furthermore, the preparation method of the above anti-skin aging cyclohexapeptide compound specifically comprises: A chain-like fully protected hexameric polypeptide was prepared by conventional polypeptide domain synthesis method; The fully protected hexapeptide is dissolved in an organic solvent and stirred to react under the conditions of a catalytic system to form a cyclohexapeptide; The cyclohexapeptide is cut and purified to obtain the anti-skin aging cyclohexapeptide compounds.
[0022] Furthermore, conventional synthesis methods for the above-mentioned polypeptide domains include solid phase synthesis or liquid phase synthesis, and the operations involved are generally understood by those skilled in the art.
[0023] Furthermore, the catalytic system includes DIC, HOBt and DIEA.
[0024] Another object of the present invention is to provide the use of the above-mentioned anti-skin aging cyclohexapeptide compounds in the preparation of cosmetics.
[0025] Compared with the prior art, the present invention has the following beneficial effects: The series of anti-skin aging cyclohexapeptide compounds prepared by the present invention have better skin repair effect and have great application prospects in the field of cosmetics. collalb The gene expression ability is significantly improved, which can significantly enhance the formation of collagen and play a better anti-wrinkle effect; at the same time, the series of cyclic hexapeptide compounds prepared have better promotion FLG The ability of gene expression can significantly enhance its ability to promote the formation of related proteins, better improve the state of the skin's stratum corneum, and show better effect in enhancing the skin barrier.
[0026] Therefore, the present invention provides an anti-skin aging cyclic hexapeptide compound and a preparation method thereof. The hexapeptide compound has better skin repair effect and significantly enhanced anti-wrinkle effect; at the same time, it has better skin barrier enhancement effect and can be better applied in the cosmetics field. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is a high performance liquid chromatogram of the cyclohexapeptide compound E1 prepared in Example 1 of the present invention; Figure 2 The mass spectrum of the cyclohexapeptide compound E1 prepared in Example 1 of the present invention; Figure 3 The cyclohexapeptide compounds prepared in Examples 1 to 8 of the present invention promote collalb Gene expression test results; Figure 4 The cyclohexapeptide compounds prepared in Examples 9 to 16 of the present invention promote collalb Gene expression test results; Figure 5 The cyclohexapeptide compounds prepared in Examples 1 to 8 of the present invention promote FLG Gene expression test results; Figure 6 The cyclohexapeptide compounds prepared in Examples 9 to 16 of the present invention promote FLG Gene expression test results. DETAILED DESCRIPTION
[0028] The technical solution of the present invention is further described in detail below in conjunction with specific implementations and drawings: Embodiment 1: Synthesis of anti-skin aging cyclohexapeptide compound E1: S1: CTC resin (6.3 g, 6.25 mmol) was placed in a 125 mL solid phase synthesis reactor, and amino acid Fmoc-Gly-OH (3.72 g, 12.5 mmol) was added, and 60 mL of dichloromethane (DCM) was added, and DIEA (4.35 mL) was added, and the reaction was carried out at 25 °C for 3 hours, and 6.25 mL of methanol was added and the reaction was carried out for 5 minutes; the resin was filtered, and washed with 60 mL of dichloromethane (DCM) twice, 60 mL of methanol twice, and 60 mL of DMF twice; 65 mL of 20% Pip / DMF solution was added, and the reaction was stirred for 30 minutes, and the resin was filtered to remove the protective solution, and then washed with 65 mL of DMF solution for 6 times, and dried for use; S2: Take Fmoc-Pro-OH (5.06g, 15mmol) and HOBt (2.03g, 15mmol) in a 100mL beaker, cool to 4℃, add 25mL of DMF solution and DIC (2.3mL, 15mmol) and let it stand for 20 minutes, then add the solution in the 100mL beaker to a 125mL solid phase synthesis reactor, stir and react for 1.5 hours, and the reaction is completed; wash the resin with DMF solution three times, 65mL each time; after washing, add 65mL of 20% Pip / DMF solution, stir and react for 30min, filter to remove the protective solution, then wash with 65mL of DMF solution 6 times, and drain for standby use; S3: Take Fmoc-Gln(Trt)-OH (9.16 g, 15 mmol) and HOBt (2.03 g, 15 mmol) in a 100 mL beaker, cool to 4 °C, add 25 mL of DMF solution and DIC (2.3 mL, 15 mmol) and let it stand for 20 minutes, then add the solution in the 100 mL beaker to a 125 mL solid phase synthesis reactor, stir and react for 1.5 hours, and the reaction is completed; wash the resin with DMF solution three times, 65 mL each time; after washing, add 65 mL of 20% Pip / DMF solution, stir and react for 30 minutes, filter to remove the protection solution, then wash with 65 mL of DMF solution 6 times, and drain for standby use; S4: Take Fmoc-Gly-OH (4.46 g, 15 mmol) and HOBt (2.03 g, 15 mmol) in a 100 mL beaker, cool to 4 °C, add 25 mL of DMF solution and DIC (2.3 mL, 15 mmol) and let it stand for 20 minutes, then add the solution in the 100 mL beaker to a 125 mL solid phase synthesis reactor, stir and react for 1.5 hours, and the reaction is completed; wash the resin with DMF solution three times, 65 mL each time; after washing, add 65 mL of 20% Pip / DMF solution, stir and react for 30 minutes, filter to remove the protective solution, then wash with 65 mL of DMF solution 6 times, and drain for standby use; S5: Take Fmoc-Pro-OH (5.06g, 15mmol) and HOBt (2.03g, 15mmol) in a 100mL beaker, cool to 4℃, add 25mL of DMF solution and DIC (2.3mL, 15mmol) and let it stand for 20 minutes, then add the solution in the 100mL beaker to a 125mL solid phase synthesis reactor, stir and react for 1.5 hours, and the reaction is completed; wash the resin with DMF solution three times, 65mL each time; after washing, add 65mL of 20% Pip / DMF solution, stir and react for 30min, filter to remove the protective solution, and then wash with 65mL of DMF solution 6 times, 65mL of methanol 2 times, 65mL of DCM solution 2 times, and 65mL of methanol 2 times; S6: Take Fmoc-Gln(Trt)-OH and HOBt (2.03 g, 15 mmol) in a 100 mL beaker, cool to 4 °C, add 25 mL of DMF solution and DIC (2.3 mL, 15 mmol) and let stand for 20 minutes, then add the solution in the 100 mL beaker to a 125 mL solid phase synthesis reactor, stir and react for 1.5 hours, and the reaction is complete; wash the resin with DMF solution three times, 65 mL each time; after washing, proceed to the next step; add 65 mL of 20% Pip / DMF solution, stir and react for 30 minutes, filter to remove the protective solution, then wash 6 times with 65 mL of DMF solution, and drain to proceed to the next step; S7: vacuum drying, adding 200 mL of 1% TFA / DCM solution, stirring and reacting at 30°C for 30 minutes, filtering, removing the resin, and obtaining a filtrate; the filtrate was dried to obtain the fully protected peptide H-Gly-Pro-Gln(Trt)-Gly-Pro-Gln(Trt)-OH; S8: Dissolve the fully protected peptide in 1.4 L of dichloromethane (DCM), add DIC (1.54 mL, 10 mmol), HOBt (1.35 g, 10 mmol), and DIEA (1.74 mL, 10 mmol), and react at 30 °C with stirring for 14 hours to form Cyclo (Gly-Pro-Gln (Trt) -Gly-Pro-Gln (Trt)), concentrate to remove DCM, and proceed to the next step; S9: Cyclo(Gly-Pro-Gln(Trt)-Gly-Pro-Gln(Trt)) was cleaved with TFA / TIS / H2O=90 / 5 / 5 (70 mL) for 2.5 hours, and the cleavage solution was added to 700 mL of tert-butyl methyl ether (4°C) solution to precipitate a white solid, which was centrifuged to obtain a white solid crude peptide; the white solid crude peptide was dried under vacuum to obtain a crude peptide powder Cyclo(Gly-Pro-Gln-Gly-Pro-Gln); the refined product Cyclo(Gly-Pro-Gln-Gly-Pro-Gln) was obtained after lyophilization by reverse phase C18 preparative chromatography (HPLC as shown in FIG. Figure 1 Its chemical structure is shown below:
[0029] 1 H NMR (500 MHz, D2O), δ ppm∶4.50, 4.39 (m, 4H, CH), 4.10~4.15 (dd, 4H, CH2), 3.62, 3.45, 2.27, 1.98~2.15 (12H, CH2), 2.01~2.10 (8H, CH2). like Figure 2 As shown, HRMS(ESI): Calcd for C 24 H 36 N8O8, m / z [M+H] + , 565.0.
[0030] Embodiment 2: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E2 is: Cycle (Gly-Pro-Asn-Gly-Pro-Asn); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0031] 1 H NMR (500 MHz, D2O), δ ppm ∶4.72, 4.34 (m, 4H, CH), 4.05~4.10 (dd, 4H, CH2), 3.57, 3.48, 2.35, 1.90~2.10 (12H, CH2), 2.75, 2.43 (m, 4H, CH2). HRMS (ESI):Calcd for C 22 H 32 N8O8, m / z [M+H] + , 537.2.
[0032] Embodiment 3: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E3 is: Cycle (Gly-Pro-Glu-Gly-Pro-Glu); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0033] 1 H NMR (500 MHz, D2O), δ ppm∶4.45, 4.40 (m, 4H, CH), 4.13~4.18 (dd, 4H, CH2), 3.57, 3.40, 2.34, 2.01~2.19 (12H, CH2), 2.41, 2.09 (, 8H, CH2). HRMS (ESI):Calcd for C 24 H 34 N6O 10 , m / z [M+H] + , 567.0.
[0034] Embodiment 4: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E4 is: Cycle (Gly-Pro-Asp-Gly-Pro-Asp); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0035] 1 H NMR (500 MHz, D2O), δ ppm ∶4.87, 4.46 (m, 4H, CH), 4.09~4.13 (dd, 4H, CH2), 3.55, 3.41, 2.33, 1.92~2.10 (12H, CH2), 2.94, 2.59 (m, 4H, CH2). HRMS (ESI):Calcd for C 22 H 30 N6O 10 , m / z [M+H] + , 539.2.
[0036] Embodiment 5: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E5 is: Cycle (Gly-Hyp-Gln-Gly-Hyp-Gln); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0037] 1 H NMR (500 MHz, D2O), δ ppm∶4.47, 4.41, 4.10 (m, 6H, CH), 4.11~4.17 (dd, 4H, CH2), 3.79, 3.50, 2.52, 2.28 (8H, CH2), 2.00~2.05 (8H, CH2). HRMS (ESI): Calcdfor C 24 H 36 N8O 10 , m / z [M+H] + , 597.3.
[0038] Embodiment 6: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E6 is: Cycle (Gly-Hyp-Asn-Gly-Hyp-Asn); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0039] 1 H NMR (500 MHz, D2O), δ ppm ∶4.85, 4.44, 4.13 (m, 6H, CH), 4.09~4.13 (dd, 4H, CH2), 3.75, 3.48, 2.49, 2.25 (8H, CH2), 2.74, 2.50 (4H, CH2). HRMS (ESI): Calcdfor C 22 H 32 N8O 10 , m / z [M+H] + , 569.2.
[0040] Embodiment 7: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E7 is: Cycle (Gly-Hyp-Glu-Gly-Hyp-Glu); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0041] 1 H NMR (500 MHz, D2O), δ ppm∶4.41, 4.37, 4.08 (m, 6H, CH), 4.08~4.11 (dd, 4H, CH2), 3.74, 3.52, 2.51, 2.24 (8H, CH2), 2.37, 2.04 (8H, CH2). HRMS (ESI): Calcdfor C 24 H 34 N6O 12 , m / z [M+H] + , 599.2.
[0042] Embodiment 8: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E8 is: Cycle (Gly-Hyp-Asp-Gly-Hyp-Asp); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0043] 1 H NMR (500 MHz, D2O), δ ppm ∶4.85, 4.42, 4.11 (m, 6H, CH), 4.05~4.09 (dd, 4H, CH2), 3.70, 3.54, 2.46, 2.21 (8H, CH2), 2.98, 2.63 (4H, CH2). HRMS (ESI): Calcdfor C 22 H 30 N6O 12 , m / z [M+H] + , 571.1.
[0044] Embodiment 9: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E9 is: Cycle (Gly-Pip-Gln-Gly-Pip-Gln); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0045] 1 H NMR (500 MHz, D2O), δ ppm∶: 4.49, 4.38 (4H, CH), 4.09~4.12 (dd, 4H, CH2), 3.62, 3.53, 2.05, 1.54~1.80 (16H, CH2), 2.01~2.07 (8H, CH2). HRMS (ESI):Calcd for C 26 H 40 N8O8, m / z [M+H] + , 593.3.
[0046] Embodiment 10: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E10 is: Cycle (Gly-Pip-Asn-Gly-Pip-Asn); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0047] 1 H NMR (500 MHz, D2O), δ ppm ∶: 4.89, 4.35 (4H, CH), 4.10~4.14 (dd, 4H, CH2), 3.60, 3.47, 2.00, 1.60~1.85 (16H, CH2), 2.85, 2.53 (4H, CH2). HRMS (ESI):Calcd for C 24 H 36 N8O8, m / z [M+H] + , 565.3.
[0048] Embodiment 11: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E11 is: Cycle (Gly-Pip-Glu-Gly-Pip-Glu); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0049] 1 H NMR (500 MHz, D2O), δ ppm∶: 4.41, 4.35 (4H, CH), 4.08~4.12 (dd, 4H, CH2), 3.55, 3.46, 1.98, 1.45~1.74 (16H, CH2), 2.42, 2.01 (8H, CH2). HRMS (ESI):Calcd for C 26 H 38 N6O 10 , m / z [M+H] + , 595.3.
[0050] Embodiment 12: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E12 is: Cycle (Gly-Pip-Asp-Gly-Pip-Asp); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0051] 1 H NMR (500 MHz, D2O), δ ppm ∶: 4.90, 4.30 (4H, CH), 4.07~4.11 (dd, 4H, CH2), 3.54, 3.44, 2.07, 1.60~1.88 (16H, CH2), 2.99, 2.71 (4H, CH2). HRMS (ESI):Calcd for C 24 H 34 N6O 10 , m / z [M+H] + , 567.2.
[0052] Embodiment 13: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E13 is: Cycle(Gly-β-HomoPro-Gln-Gly-β-HomoPro-Gln); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0053] 1 H NMR (500 MHz, D2O), δ ppm∶: 4.48, 3.79 (4H, CH), 4.12~4.16 (dd, 4H, CH2), 3.57, 3.42, 2.00~2.06, 1.96, 1.81 (12H, CH2), 2.58, 2.30 (m, 4H, CH2), 2.03~2.09 (8H, CH2). HRMS (ESI): Calcd for C 26 H 40 N8O8, m / z [M+H] + , 593.3.
[0054] Embodiment 14: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E14 is: Cycle(Gly-β-HomoPro-Asn-Gly-β-HomoPro-Asn); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0055] 1 H NMR (500 MHz, D2O), δ ppm ∶: 4.79, 3.71 (4H, CH), 4.10~4.15 (dd, 4H, CH2), 3.48, 3.39, 2.05~2.10, 1.93, 1.77 (12H, CH2), 2.51, 2.26 (m, 4H, CH2), 2.86, 2.57 (4H, CH2). HRMS (ESI): Calcd for C 24 H 36 N8O8, m / z [M+H] + , 565.3.
[0056] Embodiment 15: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E15 is: Cycle(Gly-β-HomoPro-Glu-Gly-β-HomoPro-Glu); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0057] 1 H NMR (500 MHz, D2O), δ ppm∶: 4.45, 3.76 (4H, CH), 4.04~4.09 (dd, 4H, CH2), 3.46, 3.38, 2.03~2.08, 1.87, 1.74 (12H, CH2), 2.48, 2.27 (m, 4H, CH2), 2.35, 2.11 (8H, CH2). HRMS (ESI): Calcd for C 26 H 38 N6O 10 , m / z [M+H] + , 595.3.
[0058] Embodiment 16: The amino acid sequence of the anti-skin aging cyclohexapeptide compound E16 is: Cycle(Gly-β-HomoPro-Asp-Gly-β-HomoPro-Asp); The synthesis method can be synthesized by selecting the required amino acids or compounds according to the synthesis procedure shown in Example 1. The chemical structure is shown below:
[0059] 1 H NMR (500 MHz, D2O), δ ppm ∶: 4.90, 3.81 (4H, CH), 4.07~4.12 (dd, 4H, CH2), 3.51, 3.41, 2.04~2.07, 1.92, 1.77 (12H, CH2), 2.50, 2.22 (m, 4H, CH2), 2.89, 2.65 (4H, CH2). HRMS (ESI): Calcd for C 24 H 34 N6O 10 , m / z [M+H] + , 567.2.
[0060] Comparative Example 1: A method for preparing a chain hexapeptide compound D1: The fully protected polypeptide H-Gly-Pro-Gln(Trt)-Gly-Pro-Gln(Trt)-OH obtained in step S7 of Example 1 was cleaved with TFA / TIS / H2O=90 / 5 / 5 (70 mL) for 2.5 hours, and the cleavage solution was added to 700 mL of tert-butyl methyl ether (4° C.) solution to precipitate a white solid. The solid was centrifuged to obtain a white solid crude peptide. The white solid crude peptide was dried under vacuum to obtain a crude peptide powder Gly-Pro-Gln-Gly-Pro-Gln, which was then purified by reverse phase C18 preparative chromatography and freeze-dried to obtain a fine product Gly-Pro-Gln-Gly-Pro-Gln.
[0061] Comparative Example 2: A method for preparing chain hexapeptide compound D2 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 2.
[0062] Comparative Example 3: A method for preparing chain hexapeptide compound D3 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 3.
[0063] Comparative Example 4: A method for preparing chain hexapeptide compound D4 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 4.
[0064] Comparative Example 5: A method for preparing chain hexapeptide compound D5 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 5.
[0065] Comparative Example 6: A method for preparing chain hexapeptide compound D6 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 6.
[0066] Comparative Example 7: A method for preparing chain hexapeptide compound D7 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 7.
[0067] Comparative Example 8: A method for preparing chain hexapeptide compound D8 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 8.
[0068] Comparative Example 9: A method for preparing chain hexapeptide compound D9 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 9.
[0069] Comparative Example 10: A preparation method of chain hexapeptide compound D10 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 10.
[0070] Comparative Example 11: A method for preparing chain hexapeptide compound D11 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 11.
[0071] Comparative Example 12: A method for preparing chain hexapeptide compound D12 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 12.
[0072] Comparative Example 13: A method for preparing chain hexapeptide compound D13 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 13.
[0073] Comparative Example 14: A method for preparing chain hexapeptide compound D14 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 14.
[0074] Comparative Example 15: A method for preparing chain hexapeptide compound D15 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 15.
[0075] Comparative Example 16: A method for preparing chain hexapeptide compound D16 The raw materials and preparation method used in this example are basically the same as those in Comparative Example 1, except that the fully protected polypeptide used is the fully protected polypeptide obtained in step S7 of Example 16.
[0076] Test Example 1: 1. Determination of anti-wrinkle efficacy 1.1 Detection Reagents Anhydrous ethanol (Batch No. 20200302, Sinopharm Chemical Reagent Co., Ltd., China); iTaq UniversalSYBR Green Supermix (Cat. No. 1725124, Bio-rad, USA); FastQuant RT Kit (With gDNase) (KR106, Tiangen Biochemical Technology (Beijing) Co., Ltd., China); RNA-Quick Purification Kit (RNA Rapid Extraction Kit) (RN001, Shanghai Yishan Biotechnology Co., Ltd., China).
[0077] 1.2 Testing animals Zebrafish strain: wild-type AB strain; zebrafish age: 4 days after fertilization (4dpf); adult fish rearing and breeding methods: in line with the requirements of the international AAALAC certification (certification number: 001458).
[0078] 1.3 Detection Method (1) Fish preparation: randomly selected zebrafish were divided into groups of 30 each, with the number of groups set according to the number of samples to be measured, and then placed in a 6-well plate; (2) Sample addition: Add samples at a concentration of 0.003% to a 6-well plate, with a fixed volume of 3 mL per well. Set up a normal control group and set up three biological replicates in total. (3) Incubation: Incubate each experimental group at 28°C in the dark for 24 h; (4) RNA extraction: The total RNA of each group of zebrafish was extracted using an RNA rapid extraction kit, and the concentration and purity of the total RNA were measured using a UV-visible spectrophotometer; (5) q-PCR detection: Take 2.00 μg of total RNA from zebrafish samples and synthesize 20.0 μL of cDNA according to the instructions of the cDNA first-strand synthesis kit. Use q-PCR for detection β-actin and collalb gene expression; (6) Data processing: β-actin As an internal reference for gene expression, collalbRelative RNA expression of genes:
[0079] The above test was performed on the cyclic hexapeptides prepared in Examples 1-16 and the corresponding chain hexapeptides prepared in Comparative Examples 1-16. The results are as follows: Figure 3-4 As shown. Figure 3-4 It can be seen that compared with the normal control group, the chain hexapeptide prepared by Examples 1-16 of the present invention was used to treat collalb The relative expression of genes was significantly increased, indicating that the series of chain hexapeptide compounds obtained have good promoting collalb The effect of gene expression can promote the formation of type I collagen, reduce the loss of collagen, and thus improve the smoothness of the skin, and the anti-wrinkle effect is significantly enhanced. At the same time, after treatment with the cyclohexapeptide compounds prepared in Examples 1-16 collalb The relative gene expression level was significantly higher than that of the chain hexapeptide, indicating that the series of cyclic hexapeptide compounds prepared by the present invention have better promoting collalb It can significantly enhance its gene expression ability and promote collagen formation, thus improving skin condition and achieving better anti-wrinkle effect.
[0080] 2. Determination of skin barrier enhancement efficacy 2.1 Detection Reagents DMEM basal medium (lot number 8121012, Thermo Fisher Scientific (China) Co., Ltd., China); D-Hanks (without calcium and magnesium, without phenol red) (lot number 20210830, Beijing Solebow Technology Co., Ltd., China); double antibody solution (catalog number SV30010, Hyclone, USA); fetal bovine serum (lot number 12J098, ExCellBio, China); iTaq UniversalSYBR Green Supermix (catalog number 1725124, Bio-rad, USA); FastQuant RT Kit (With gDNase) kit (KR116-02, Tiangen Biochemical Technology (Beijing) Co., Ltd., China); RNA-Quick Purification Kit (RNA rapid extraction kit) (RN001, Shanghai Yishan Biotechnology Co., Ltd., China).
[0081] 2.2 Detection of cells Cell type: Humanized keratinocytes HaCaT, adherent cells; Culture medium: DMEM, containing 10% fetal bovine serum and 1% double antibody (penicillin and streptomycin); Culture conditions: The cells were revived and cultured for two generations in a constant temperature incubator at 37°C, 5% CO2, and 95% humidity before the experiment.
[0082] 2.3 Detection Method (1) Cell inoculation: 2.00 mL of a 6×10 5 The cell suspension of cells / well was inoculated into a 6-well plate, and a normal control group was set up in the experiment; the cells were cultured in a constant temperature incubator at 37°C, 5% CO2, and 95% humidity for 24 h; (2) Sample addition: Samples were added to the corresponding 6-well plates at a concentration of 0.5%, and the normal control group was replaced with culture medium; (3) Culture: The 6-well plate was cultured in a constant temperature incubator at 37°C, 5% CO2, and 95% humidity for 24 h. (4) RNA extraction: The total RNA of each group of zebrafish was extracted using an RNA rapid extraction kit, and the concentration and purity of the total RNA were measured using a UV-visible spectrophotometer; (5) q-PCR detection: Take 1.00 μg of total RNA from zebrafish samples and synthesize 20.0 μL of cDNA according to the instructions of the cDNA first-strand synthesis kit. Use q-PCR for detection FLG gene expression; (6) Data processing: β-actin As an internal reference for gene expression, FLG Relative RNA expression of genes:
[0083] The above test was performed on the cyclic hexapeptides prepared in Examples 1-16 and the corresponding chain hexapeptides prepared in Comparative Examples 1-16. The results are as follows: Figure 5-6 As shown. Figure 5-6 It can be seen that compared with the normal control group, the chain hexapeptide prepared by Examples 1-16 of the present invention was used to treat FLG The relative expression of genes was significantly increased, indicating that the series of chain hexapeptide compounds obtained have good promoting FLG The effect of gene expression can promote the formation of filaggrin, enhance the moisture retention capacity of the stratum corneum, improve the state of the stratum corneum, and thus effectively enhance the skin barrier function. FLG The relative gene expression level was significantly higher than that of the chain hexapeptide, indicating that the series of cyclic hexapeptide compounds prepared by the present invention have better promoting FLG It can significantly enhance the gene expression ability and promote the formation of related proteins, thus improving the state of the skin stratum corneum and enhancing the skin barrier.
[0084] Test Example 2: Skin irritation test of anti-wrinkle cyclic hexapeptide compounds Data and grouping of the test population: Female volunteers aged 35-55 with healthy skin and no history of skin allergies were selected and randomly divided into groups of 10 people in each group. Test method: Select a qualified patch tester, use a closed patch test method, drop about 0.02mL of anti-skin aging cyclohexapeptide compound sample into the patch tester, and apply a special tape to the back of the subject. Remove the sample after 24 hours, and observe the skin reaction at 0.5h, 6h, 12h, 24h, and 48h after removal, and record the results according to the skin reaction grading standard in the "Cosmetic Hygiene Standards".
[0085] From the results of the skin irritation test, it can be seen that the skin reactions of the subjects in each group were observed at 0.5h, 6h, 12h, 24h and 48h through the above experiment, and no adverse reactions such as erythema, herpes, edema, etc. appeared on the skin, indicating that the anti-skin aging cyclohexapeptide compounds E1-E16 of the present invention have little irritation to the skin and are safe to use.
[0086] The conventional techniques in the above embodiments are prior arts known to those skilled in the art, and thus will not be described in detail here.
[0087] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. An anti-skin aging cyclohexapeptide compound, the general structural formula of which is shown in Formula I: I, In Formula I, n is independently selected from 0: R1, R2 are independently selected from (CH2) m When COOA1, m is selected from 0-24, A1 is selected from H, C 1-24 Alkyl, C 3-24 Cycloalkyl, C 3-10 One of heterocycloalkyl; R3, R4, R5, R6, R7, R8 are independently selected from H; R1, R2 are independently selected from (CH2) m When CONA2A3, m is selected from 0-1, A2 and A3 are independently selected from H, C 1-24 Alkyl, C 3-24 Cycloalkyl, C 3-10 One of heterocycloalkyl; R3, R4, R5, R6, R7, R8 are independently selected from H; Or, n is independently selected from 1: R1, R2 are independently selected from H, (CH2) m COOA1, (CH2) m CONA2A3, m is independently selected from 0-24; A1, A2, A3, A4 are independently selected from H, C 1-24 Alkyl, C 3-24 Cycloalkyl, C 3-10 One of the heterocycloalkyl groups; R3, R4, R5, R6, R7, and R8 are independently selected from H.
2. The anti-skin aging cyclohexapeptide compound according to claim 1, characterized in that: The R1 and R2 are the same.
3. The anti-skin aging cyclohexapeptide compound according to claim 2, characterized in that: The R1 and R2 are selected from (CH2) m COOH, (CH2) m One of CONH2.
4. The anti-skin aging cyclohexapeptide compound according to claim 3, characterized in that: The n is selected from 1, and m is selected from 1 or 2.
5. The anti-skin aging cyclohexapeptide compound according to claim 1, characterized in that: The structure of the anti-skin aging cyclohexapeptide compound is shown below: 。 6. The method for preparing the anti-skin aging cyclohexapeptide compound according to claim 1, comprising: Firstly, a chain hexapeptide is synthesized, and then a cyclic hexapeptide compound is obtained through a ring-forming reaction.
7. Use of the anti-skin aging cyclohexapeptide compound according to claim 1 in the preparation of cosmetics.
